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Abstract. Epidemiological and experimental studies suggest that 1,25-dihydroxyvitamin D3 (1,25D) 
plays a neuroprotectiverole in neurodegenerative diseases including Alzheimer’s disease. Most of the 
experimental data regarding the genes regulatedby this hormone in brain cells have been obtained 
with neuron and glial cells. Pericytes play a critical role in brain function thatencompasses their 
classical function in blood-brain barrier control and maintenance. However, the gene response of 
brain pericyteto 1,25D remains to be investigated. Analyses of the transcriptomic response of human 
brain pericytes to 1,25D demonstrate thathuman brain pericytes in culture respond to 1,25D by 
regulating genes involved in the control of neuroinflammation. In addition,ericytes respond to the 
pro-inflammatory cytokines tumor necrosis factor and Interferon  by inducing the expression of 
theCYP27B1 gene which is involved in 1,25D synthesis. Taken together, these results suggest that 
neuroinflammation could triggerthe synthesis of 1,25D by brain pericytes, which in turn respond to 
the hormone by a global anti-inflammatory response. Thesefindings identify brain pericytes as a 
novel 1,25D-responsive cell type and provide additional evidence for the potential value ofvitamin D 
in the prevention or therapy of Alzheimer’s disease and other neurodegenerative/neuropsychiatric 
diseases associatedwith an inflammatory component. 
  
INTRODUCTION 
Recent data suggest a role for 1,25dihydroxyvitaminD3 (1,25D) in the prevention or in the therapy 
of neurodegenerative and neuropsychiatric diseasesincluding multiple sclerosis and Alzheimer’s 
disease(AD) (for recent reviews, see [1–10]). 1,25D is a secosteroidhormone produced from vitamin 
D througha two-step hydroxylation process successively producing25-hydroxyvitamin D3 (25D) and 
vitaminD’s most active metabolite 1,25D. This last stepis catalyzed by the 25-Hydroxyvitamin D3 
1alpha-Hydroxylase named CYP27B1. Inactivation of 1,25Doccurs through another hydroxylation step 
catalyzedby the vitamin D 24-Hydroxylase named CYP24A1, and generating 1,24,25trihydroxyvitamin 
D3 [11, 12].1,25D regulates the transcription of its cell specifictarget genes by interacting with a 
protein named vitaminD receptor (VDR). The presence of VDR in brain[13–16], the capacity of 1,25D 
to regulate the expressionof neurotrophic factors (for reviews, see [17]),and its anti-inflammatory 
potential [2, 18] are strongarguments in favor of a role for 1,25D in brain function.Regarding brain 
diseases, many recent studiesreport an association between vitamin D insufficiencyand 
neurodegenerative/neuropsychiatric disorders [5,7, 10, 19, 20]. Experimental evidence also 
demonstratea preventive or therapeutic potential for 1,25Din brain disorders including multiple 
sclerosis, Parkinson’sdisease, AD, and traumatic brain injury (forrecent reviews, see *21–24]). 
Investigating the generesponse to vitamin D in brain cells is critical forunderstanding the molecular 
basis of its neuroprotectiveeffect. Most of the experimental data regarding thepotential of 1,25D to 
regulate the expression of genesable to prevent or delay the progression of 
neurodegenerativediseases have been obtained in vitro usingbrain-derived cells. These include 
neurons and macroor microglial cells (see [25–32]). However, little attentionhas been given to 
another abundant brain cell type,the brain pericyte.Pericytes are microvessel cells that wrap 
aroundendothelial cells [33–35]. The pericyte-to-endotheliaratio is 1 : 3, and the total length of 
capillaries inhuman brain is around 400 miles [36, 37]. The edge-toedgeinter-microvessels distance in 
rat brain is around20μm in gray matter and 30μm in white matter [38].This means that pericytes are 
very close to everyneuronal cell. Because of their perivascular localization,pericytes are components 
of the neurovascularunit (NVU), an anatomical and functional entity associatingneurons, glial and 
immune cells, endothelialcells, pericytes, and the extracellular matrix [33–35,39, 40]. How brain 
pericytes communicate with glialand neuronal cells in NVU is still largely unknown,but they are, 
however, essential for proper functionsof neurons [36, 41]. In addition to their role in 
angiogenesis,vessel maintenance, and blood-brain barrierformation and functions [33, 35], brain 
pericytes alsocontribute to immune and inflammatory responsesby synthesizing pro-inflammatory 
cytokines includingCXCL8/IL-8, CXCL11/ITAC, CCL5/Rantes, tumornecrosis factor-alpha (TNF-), 
interleukin-1β(IL-1β),and interleukin-6 (IL-6) [42]. They participate to theadaptive immune response 
[43] and also have animmunosuppressive function by decreasing T lymphocyte proliferation [44]. The 
importance of pericytesin brain function is assessed by the observation thatage-dependent vascular 
damage in pericyte-deficientmice precedes neuronal degenerative changes, learningimpairment, 
memory deficiency, and the neuroinflammatoryresponse [41]. Pericyte loss or dysfunctioninfluences 
multiple steps of AD in several experimentalmodels [36, 41, 45]. Hence, targeting brain pericyteis 
now considered as a novel therapeutic option forAD [39, 41, 45, 46]. The emerging evidence for arole 
of vitamin D in brain function and its potentialpreventive and therapeutic interest in the 
managementof neurodegenerative disease prompted us to analyzethe transcriptomic response of 
human brain pericyte to1,25D. Our results provide evidence for a functionalrelationship between 
vitamin D and pericytes in thecontrol of inflammation that could explain some ofthe anti-
inflammatory and neuroprotective effects ofvitamin D. 
MATERIAL AND METHODS 
Cell culture 
Human brain pericytes and human brain endothelialcells were obtained from ScienCell Research 
Laboratories(San Diego, CA, USA). Cells were culturedon poly-lysine coated culture dishes according 
tothe provider instructions. Briefly, the growth mediumfor pericytes was made with Pericyte Basal 
CultureMedium supplemented with 2% fetal bovineserum, with Pericyte Cell Growth Supplement 
andwith penicillin and streptomycin, all from Science-Cell Research Laboratories (San Diego, CA, 
USA). 
Brain endothelial cells were cultured in EndothelialBasal Culture Medium supplemented with 
EndothelialGrowth Supplement and with penicillin and streptomycin,all from ScienCell Research 
Laboratories. Inthe absence of a definitive pan-marker for pericytes, immunophenotyping of 
pericytes relies on the use of apanel of different markers [34]. Positive markers caninclude PDGFRβ, 
nestin, and CD13/aminopeptidaseN, whereas Ve-Cad can be used as a negative marker. 
Immunophenotyping of our cell cultures demonstrateda homogeneous positive labelling forPDGFR_, 
nestin,CD13/aminopeptidase N and no detectable synthesisof the endothelial marker VE-Cadherin 
(SupplementaryFig. 1A-D). On the contrary, brain endothelialcells stained positively for the 
endothelial markerVE-Cadherin (Supplementary Fig. 1E). TNF- andInterferon- (Peprotech, Neuilly-
sur-Seine, France)were used at 50 ng/ml. 
 
Western blot analysis 
For western blot analysis, cell pellets were resuspendedand lysed in RIPA buffer (Cell Signaling 
Technology, Danvers, USA) supplemented with completeProtease Inhibitor Cocktail (Cell Signaling 
Technology, Danvers, USA). The proteins (40 μg)were resolved with 8% polyacrylamide gel and 
transferredonto the Hybond N+ membrane (Amersham,Velizy-Villacoublay, France) according to 
standardprotocols. Blots were then probed with the VDRantibody N20 (Santa Cruz, sc-1009) or D6 
(SantaCruz, sc-13133), followed by incubation with thecorresponding horseradish peroxidase 
conjugated secondaryantibodies (Santa Cruz, sc-2004 or sc-2005). 
 
RNA extraction and RT-qPCR 
2μg of total RNA were transcribed intocDNA using iScriptTM Reverse TranscriptionSupermix for 
RT.qPCR (BioRad Laboratories, Marnes-la-Coquette, France). PCR primers(Eurogentec, Angers, 
France) for each gene weredesigned using the Universal ProbeLibrary AssayDesign Center 
(https://www.roche-applied-science.com/sis/rtpcr/upl/ezhome.html) and sequences of theprimers 
used are given as Supplementary Table 1.Then real-time PCRs were performed accordingto the SYBR 
Green methodology using theSsoAdvancedTM SYBRR Green Supermix (BioRadLaboratories, Marnes-
la-Coquette, France), on aCFX96 TouchTMReal-Time PCR Detection System (BioRadLaboratories, 
Marnes-la-Coquette, France).Reference genes are _ actin and glyceraldehyde- 
3-phosphate dehydrogenase (GAPDH), whoseexpressions were not affected by 1,25D according 
to our Affymetrix data (data not shown). Analyses were performed as previously described [25] with 
CFX ManagerTM software (BioRad Laboratories,  Marnes-la-Coquette, France) using __Ct method. 
Each qPCR was performed in triplicate for PCR yieldvalidation and all reactions were performed on 
threedifferent biological samples. Data were quantifiedrelative to gene expressions of pericyte cells 
without1,25D treatment, which was standardized to 100.The statistical validation was given by the 
CFXManager software and p < 0.005 was considered significant. 
 
Gene expression profiling 
Total RNA (300 ng) extracted as described abovewas reverse transcribed and labelled with 3 prime 
IVTExpress kit (Affymetrix, High Wycombe, UK) followingthe manufacturer’s instructions. Labelled 
sampleswere hybridized on GeneChipHumanGenomeU133Plus2.0 (Affymetrix, High Wycombe, UK). 
This microarray contains over 47,000 unique transcriptswhich correspond approximately to 
39,000human genes. Subsequent wash, stain, and scan wereperformed according to the standard 
Affymetrix protocols.Raw expression data were normalized usingthe Robust Multi-array Average 
method. Experimentswere repeated twice using different RNA sampleson GeneChip (Affymetrix, 
High Wycombe, UK) andcorroborated by RT-qPCR for genes of interest. Thetranscriptomic data have 
been deposited in NCBI’sGene Expression Omnibus and are accessible throughthe Gene Expression 
Omnibus accession numberGSE54765. 
 
RESULTS 
Pericytes express VDR and respond to 1,25D byinducing CYP24A1 expression 
1,25D regulates gene expression of its target genesby interacting with the nuclear receptor VDR.We 
firstinvestigated the presence of VDR in human brain pericyte.Western blot analysis of pericyte cell 
lysateswith the VDR polyclonal antibody N20 detected thepresence of a 53 kDa band consistent with 
the presenceof VDR in these cells (Fig. 1A). A similar resultwas obtained with the VDR monoclonal 
antibody D6(Supplementary Fig. 2).We next determined the functionality of the 
1,25D/VDR transduction pathway in human brain pericytesby analyzing CYP24A1 regulation by 
1,25D(CYP24A1 is a well-known 1,25D-responsive gene[47]). Results presented in Fig. 1B 
demonstrate thestrong induction of CYP24A1 gene expression in pericytestreated for 24 hours with 
10−8M 1,25D. 
Brain pericyte transcriptomic response to 1,25D 
Having demonstrated the presence of VDR inhuman brain pericytes and the responsiveness of 
these cells to 1,25D, we analyzed the transcriptomicresponse of brain pericytes to 1,25D. RNA 
frompericytes cultured for 24 hours either with10−8M 1,25D or with vehicle only (ethanol) 
wereextracted and processed for transcriptomic analyses. Experiments were performed on two 
different RNApreparations for each condition. Twenty genes werefound upregulated by a factor of at 
least 1.7, and 5down-regulated genes were also detected (expressionratios lower than 0.7) (Table 1). 
Eight of these geneswere already described as 1,25D targets in cells otherthan pericytes. These genes 
are cytochrome P450A1(CYP24A1) [47], elongation factor Tu GTP bindingdomain (EFTUD1) [48], 
thrombomodulin (THBD)[49], odd-skipped related 2 (OSR2) [50], Kruppel-likefactor 4 (KLF4) [51], 
insulin-like growth factorbinding protein 5 (IGFBP5) [52], fatty acid binding protein 4 (FABP4) [53], 
and tumor necrosis factor(ligand) superfamily member 4 (TNFS4/OX40L)[54]. An analysis of the 25 
genes found regulated by1,25D was carried out with the GeneDeck analysis tool 
(http://www.genecards.org/). This allowed theidentification of 14 disorders associated with this 
setof genes with a p value lower than 10−5. Six of thesedisorders were inflammatory diseases: 
endotheliitis(p = 2.2×10−10), asthma (p = 1.4×10−6), rheumatoidarthritis (p=2×10−6), arthritis (p = 
5.1×10−6),inflammation (p = 6.4×10−6), and pancreatitis(p = 1.1×10−5). The other disorders include 
variouscancers and hypertension. To confirm the relationshipexisting between the transcriptomic 
response of brainpericytes to 1,25D and inflammation, a bibliographicsearch in PubMed associating 
each of these 25 genes with the keyword “inflammation” was done. Relevant 
results were obtained for 8 genes. These genes arevascular cell adhesion molecule 1 (VCAM1), 
THBD,KLF4, tumor necrosis factor alpha-induced protein6 (TNFAIP6), chordin-like 1 (CHRDL1), 
chemokine(C-C motif) ligand 2 (CCL2), FABP4, tumor necrosisfactor (ligand) superfamily member 4 
(TNFSF4).THBD, KLF4, FABP4, and TNFSF4 have alreadybeen described as 1,25D-responsive genes in 
cellsother than brain cells or pericytes [49, 51, 53, 54].Confirmatory RT-qPCR analyses were 
performed thatvalidated the transcriptomic data for the 4 remaininggenes which were not previously 
described as 1,25Dtargets (Fig. 2). These are CCL2, CHDRL1, TNFPAIP6,and VCAM-1. KLF4 and TNFSF4 
were alsoincluded as positive controls in these confirmatory 
experiments. Importantly the regulations observed areconsistent with a global anti-inflammatory 
response(see discussion below). 
Induction of CYP27B1 expression by thepro-inflammatory cytokines TNF-α andInterferon-γ 
25D is the most abundant metabolite of vitamin Din the circulation, but the most active metabolite 
is1,25D [11, 12]. Hydroxylation of 25D to active 1,25Dis required for the induction of the 1,25D-
dependentsignaling pathway [11, 12]. This reaction is carriedout by 25-Hydroxyvitamin D3 1alpha-
HydroxylaseCYP27B1, the rate limiting enzyme in 1,25D synthesis.Analysis of our transcriptomic data 
for CYP27B1failed to detect any expression for this gene in our pericytecultures (data not shown). 
Considering the globalanti-inflammatory gene response of pericytes to 1,25D, 
we hypothesized that inflammatory stimuli could upregulateCYP27B1 gene expression in these cells. 
Thiswould allow pericytes to metabolize 25D into 1,25Dand then limit the inflammatory response 
locally. Toinvestigate this point we treated brain pericytes withTNF-and Interferon- which were 
recently foundto upregulate CYP27B1 in astrocytes [55]. Figure 3showed that a treatment of 
pericytes for 24 hourswith these two inflammatory cytokines stimulated theexpression of CYP27B1. 
 
DISCUSSION 
Epidemiological studies reveal a relationshipbetween several neurodegenerative/psychiatric 
diseasesand low vitamin D levels [5, 7, 10, 19–21,57, 58]. Although association does not mean 
causation,the possible role of vitamin D as a protectiveco-factor against brain disorders is further 
supportedby data demonstrating the neuroprotective effect ofvitamin D or of its active metabolite 
1,25D in severalexperimental models of brain diseases (for recent reviews, see [1–10]). 
Understanding the molecularpathways involved in these effects is critical for optimizingclinical trials. 
At the transcriptomic level,1,25D is already known to upregulate several genes 
relevant to neuroprotection in brain cells. Several ofthese genes encode neurotrophins including NGF 
andGDNF [59–61]. 1,25D is a potent immunoregulatoryagent [2–4, 62, 63]. In neurons or glial 
cells1,25D regulates the expression of genes involved in thecontrol of neuroinflammation, such as 
cystathioninebeta-synthase, which codes for the enzyme producing the neuroprotective agent 
hydrogene sulfide [25], andgamma-glutamyltranspeptidase (gamma-GT) whichis the enzyme that 
synthesizes the antioxidant glutathione[64]. 1,25D also reduces the expression of theinflammatory 
cytokines M-CSF and TNF-_ in astrocyteschallenged with lipopolysaccharides [65], andprotects brain 
cells from nitric oxide excessive productionby down-regulating iNOS [30]. However, allthese data 
have been obtained with cells others thanpericytes, and the global gene response of pericytes 
to1,25D remained to be investigated. This point is criticalregarding the importance of pericytes in 
brain function[33–46]. The present study reveals that eight out of thetwenty five genes we found 
regulated by 1,25D in brainpericytes are related to inflammation. With exceptionof VCAM1, all of 
these genes are involved in criticalanti-inflammatory processes. This regulation is consistentwith a 
global anti-inflammatory process sincepro-inflammatory genes are found down-regulated,while anti-
inflammatory genes are upregulated. 
 
Pro-inflammatory genes down-regulated by 1,25Din pericytes 
CCL2/MCP-1 is an inflammatory chemokine thatis also able to modulate blood-brain barrier 
permeability.It is upregulated in AD patients and notablyin brain microvessels [66]. High plasma 
concentrationof CCL2 are found in mild AD [67] and is associatedwith a faster rate of cognitive 
decline during the earlystages of AD [68]. CCL2 is also associated with multiplesclerosis patients and 
experimental autoimmuneencephalomyelitis (EAE). Moreover deficiency in theCCL2 receptor CCR2 
confers resistance to EAE [69].TNFSF4/OX40L is the ligand of the OX40 receptor.The OX40-OX40L 
interaction is critical for theregulation of T cell tolerance and T-cell mediatedinflammatory diseases 
[70]. Consequently, OX40 signalingis involved in allergic inflammation [71, 72]and in multiple 
sclerosis, and is also involved inthe development of EAE [73]. Down-regulation ofTNFSF4/OX40L is 
suggested to provide a novelapproach for treating inflammatory disease [72, 
74–76].The fatty acid binding protein FABP4 acts at theinterface of metabolic and inflammatory 
pathways[77]. It is involved in the development of a chronicmetabolic inflammatory state recently 
referred asmetaflammation that connects obesity with inflammation[77]. FABP4 is associated with 
inflammatoryfactors relatedto obesity [78], and is also implicated in asthma [79] and rheumatoid 
arthritis [80]. Toour knowledge, the involvement of FABP4 and the potential of inhibitors of FABP4 
have not yet beeninvestigated in inflammatory neurodegenerative disorders. 
 
Anti-inflammatory genes upregulated by 1,25D inpericytes 
Thrombomodulin (THBD) is a well characterized1,25D responsive gene proposed as a biomarker for 
evaluating the effect of vitamin D supplementation[49]. The anti-inflammatory properties of 
thrombomodulinhave been recently reviewed [81, 82]. THBDsequesters thrombin which has pro-
inflammatoryactivities, in addition to its role in hemostasis andthrombosis. Note that thrombin is 
highly expressed inAD brain vessels and is a mediator of cerebral inflammation in AD. 
Thrombomodulin also promotes theactivation of protein C, which, in addition to its anticoagulant 
activity, also has anti-inflammatory effectsby suppressing the production of the pro-inflammatory 
cytokine TNF- [83].Tumor necrosis factor, alpha-induced protein 6(TNFAIP6/TSG6) is a secreted 
protein whose expressionis upregulated in response to pro-inflammatorycytokines such as TNF and 
IL-1. It has anti-inflammatory effects and acts as a negative feedbackmodulator by down-regulating 
the inflammatoryresponse [84].The identification of KLF4 as a 1,25D upregulatedgene is in 
agreement with a previous findingobtained with keratinocytes [51] and is in line witha general role of 
1,25D and KFL4 in the controlof inflammatory responses. KLF4 inhibits endothelialinflammation [85] 
and represses the expression ofhistidine carboxylase, which is the enzyme that convertshistidine to 
histamine, a major actor of allergyand inflammation [86]. In macrophage KLF4 promotesthe anti-
inflammatory macrophage/microglia M2 phenotype at the expanse of the M1 pro 
inflammatoryphenotype [87]. In this regard, it is worth mentioningthat M2 microglia is reported to 
drive oligodendrocytedifferentiation during CNS remyelination. Althoughsuch effects are observed 
with macrophages, they maybe relevant in the case of pericytes. Indeed these cellsare a source of 
macrophage activity, macrophage markers,phagocytosis, and antigen presentation [88]. 
Note,however, that KLF4 also increases the synthesis ofseveral pro-inflammatory cytokines in M1 
microglialcells [89]. This suggests that the effects of 1,25Don KLF4 expression could participate to the 
control of abalanced inflammatory response, thus preventing the development of chronic 
inflammation. Chordin-like protein 1 (CHRDL1), also known asVentroptin, is a bone morphogenetic 
protein-4 antagonist[90, 91]. It antagonizes the function of BMP4 bybinding to it and preventing its 
interaction with receptors.Increased expression of BMP4 mRNA withinthe hippocampus dentate 
gyrus is correlated with adecrease in cell proliferation inA_PPswe/PS1DeltaE9transgenic mice [92]. 
BMP4 is upregulated duringEAE [93], and this cytokine is also reported to mediateinflammation in 
endothelial cells [94]. Hence, thesynthesis of CHRDL1 by pericytes would protect cells 
from inflammation.Vascular adhesion molecule-1 (VCAM1) is a cellsurface protein with adhesion 
properties. It is alymphocyte adhesion molecule induced on humanendothelium by inflammatory 
stimuli [95] and hasbeen initially considered as an inflammatory marker.However, it is not clear 
whether its function is onlydirected toward the aggravation of the original insultor if, depending of 
the context, is also involved inthe restoration of homeostasis. VCAM1 plays a keyrole in the brain in 
maintaining subventricular zoneadult stem cell niche structure and function [96]. Thissuggests that 
VCAM1 could have similar functions inthe maintenance of the structure and functions of theNVUby 
regulating cell-cell junctions. Upregulation ofVCAM1 has been suggested to play a protective role 
inmaintaining the integrity of the ependymal zone duringneuroinflammation [96]. VCAM-1 depletion 
leadsto the rapid decrease of the subventricular zone neuralstem cell population, suggesting that 
chronic VCAM-1insufficiency/deficiency would lead to neural stem celldepletion [96]. 
Collectively, our gene expression data providestrong evidence that the gene response of human 
brainpericytes to 1,25D is directed toward the control ofneuroinflammation. 
 
Expression of CYP27B1 in pericytes can beinduced by an inflammatory stimulus 
1,25D results from the metabolism of 25D by 25-Hydroxyvitamin D3 1alpha-Hydroxylase (CYP27B1). 
Thus, the availability of 1,25D at the cellular leveldepends on both circulating levels of 25D, and 
CYP27B1 expression level. 25D is detected in humancerebrospinal fluid [58]. Therefore, the 
characterizationof stimuli able to induce CYP27B1 is critical.Here we report that TNF- and 
Interferon-, two inflammatory cytokines recently described to regulateCYP27B1 expression in 
astrocytes and microglial cells [55], also induce the expression of CYP27B1 in pericytes. 
Note that pericytes are reported to secrete TNF-[42]. Our data strongly suggest the existence of a 
regulatoryintracrine/autocrine feedback loop in pericytesbalancing the inflammatory potential of 
TNF- andInterferon-. A paracrine role for the 1,25D producedby pericytes in the NVU during 
inflammation can alsobe considered.In conclusion, our results point to brain pericytes and 
1,25D as two active players in the regulation of neuroinflammation.They provide additional evidence 
fora role of vitamin D metabolites in the prevention and the therapy of 
neurodegenerative/neuropsychiatric diseasesthrough the modulation of neuroinflammation.They 
also strengthened the interest of targeting brainpericytes for controlling brain disorders such as AD 
[41, 45, 46, 97, 98]. 
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Fig. 1. Human pericyte cells express VDR and respond to 1,25D3. A) Immunoblot showing the 
presence of VDR in human pericyte brain cellcultures. Lane 1, molecular weight markers; lane 2: 
pericyte cell lysate. The blot was incubated with the VDR antibody N20. B) RT-qPCR assay 
of the mRNA of the 1,25D inducible gene vitamin D 24-Hydroxylase (CYP24A1) demonstrates a 
significant increase in CYP24A1 mRNAamount when pericytes are cultured for 24 hours with 10−8 M 
1,25D3. (∗p < 0.005); A.U: arbitrary units. 
 
 
 
 
Table 1:List of differentially expressed genes in human brain pericyte cultures in the presence of 10−8 
M 1,25D (average induction fold ≥1.7 or ≤0.7compared to control cells). Fold changes are the average 
of two independent experiments. Published references for genes previously reported to 
be modulated by 1,25D are indicated. 
 
 
 
 
 
 
 
 
 
Fig. 2.Confirmatory RT-qPCR of the transcriptomic data for the genes newly identified as upregulated 
by 1,25D and involved in the regulationof inflammation. Results are depicted relative to control and 
normalized to actin and GAPDH mRNA. (∗p < 0.005 compared to control). KLF4and TNFSF4, two 
genes previously described as induced by 1,25D [51, 54], were included as positive control. CCL2, 
Chemokine (C-C motif)ligand 2; CHRDL1, chordin-like 1; KLF4, Kruppel-like factor 4; TNFAIP6, Tumor 
necrosis Factor, alpha-induced protein 6; TNFSF4, Tumornecrosis factor (ligand) superfamily member 
4; VCAM, Vascular cell adhesion molecule 1. 
 
 
 
 
Fig. 3. TNF- and Interferon-induce the expression of 25-Hydroxyvitamin D3 1alpha-Hydroxylase 
(CYP27B1) in human brain pericytes.Human brain pericytes were cultured in the presence or absence 
of TNF-(50 ng/ml) and Interferon- (50 ng/ml) for 24 hours. Then RNA were 
extracted and CYP27B1 expression quantified by RT-qPCR. (∗p < 0.005 compared to control). 
